A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Dexamethasone in Patients With Multiple Myeloma Exposed to Bortezomib, Carfilzomib, Lenalidomide and Pomalidomide and Refractory to an IMiD and a Proteasome Inhibitor
Patients with heavily pretreated, quad-exposed multiple myeloma (refractory to one PI and one IMiD) will receive selinexor 80 mg (45 mg/m2 BSA) plus low-dose dexamethasone (20 mg), both twice weekly.
Cancer (Oncology) - Multiple Myeloma,
William Bensinger, MD
Swedish Cancer Institute
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Smoldering MM.
- Plasma cell leukemia.
- MM that does not express M-protein or FLC (i.e., non-secretory MM is excluded; plasmacytomas without M-protein or FLC are excluded).
- Documented systemic amyloid light chain amyloidosis.
- Active CNS MM.